The profitability of a contract research organization can hinge on an unexpected asset: laboratory monkeys. In the world of drug safety evaluation, a research monkey serves dual roles—it is both a direct research cost for ongoing projects and a biological asset on the balance sheet. For JOINN Laboratories (China) Co., Ltd. (ASX: 603127), this duality created significant profit leverage in the first half of 2026.

Financial estimates indicate the company's attributable net profit could reach as high as 900 million yuan, representing a year-on-year increase exceeding 13 times. However, revenue growth is forecast at a maximum of only 10.5%. A substantial portion of this profit surge is attributed to fair value changes in its biological assets, a contribution that even surpasses the total pre-announced profit figure. On July 15th, shares of JOINN (ASX: 06127) opened over 12% higher on the Hong Kong exchange, underscoring the capital market's acute sensitivity to signs of a profit recovery in the CXO sector.

Key Metrics Beyond Monkey Prices

While the surge in monkey prices is a headline driver, a thorough assessment of JOINN's fundamentals requires examining several other critical indicators. New contract signings, gross margin from core operations, operating cash flow, and overseas capacity utilization rates are all vital metrics that will require consistent verification over the coming quarters.

Profit Warmth Masks Core Business Challenges

Focusing solely on the net profit growth rate can be misleading. A deeper analysis of JOINN's profit sources is necessary. The company's forecast shows that fair value changes in biological assets contributed approximately 703 million to 777 million yuan to adjusted net profit for H1 2026. In contrast, the net profit from its core laboratory services and other businesses is projected to range from a loss of 142 million yuan to a profit of 64.97 million yuan.

The company has concurrently cautioned that while industry sentiment is recovering, the lingering effects of previous price competition continue to negatively impact revenue recognition and gross margins. Therefore, despite the appearance of substantial profitability on the income statement, the core business remains in a phase of digesting low-priced contracts from the past.

This structural dynamic was already evident in 2025. That year's annual report showed JOINN's revenue fell 17.9% to 1.658 billion yuan, with non-clinical research services accounting for 95.1% of the total. The comprehensive gross margin dropped by 7.72 percentage points to 20.71%. During the same period, the company recorded a 514 million yuan gain from the fair value of biological assets, which helped lift the full-year net profit to 298 million yuan. The rebound in monkey prices improved the asset side of the balance sheet and allowed net profit to reverse course ahead of the core business.

The Dual Nature of a Critical Resource

Laboratory monkeys are both a production input and a biological asset on JOINN's books. At the end of 2025, the company owned over 20,000 non-human primates. The average market price for a 3-to-5-year-old experimental monkey was approximately 105,000 yuan. Rising prices increase the value of the existing stock of animals while simultaneously raising the direct costs for new projects. However, if project pricing adjustments lag behind changes in monkey costs, growth in new orders may not translate into improved gross margins.

Data for Q1 2026 illustrates this divergence: JOINN's revenue grew 10.02% year-on-year to 316 million yuan, while attributable net profit surged 479.67% to 238 million yuan. Within this, fair value gains on biological assets contributed 246 million yuan, whereas the laboratory services segment remained in the red, posting a loss of 28.46 million yuan. While a business recovery is underway, stable profitability from core operations has yet to be established.

Unlike conventional CXO firms, JOINN's financials carry distinct commodity cycle characteristics due to the price volatility of its key biological asset. During an upswing in monkey prices, the company can book significant asset gains. Conversely, these fair value gains may contract when prices fall. Consequently, the projected 600 million to 900 million yuan net profit primarily signals a direction of profit recovery rather than a sustainable level of normalized earnings. The central questions for fundamental analysis remain: when will the low-priced backlog be cleared, can new contracts be signed at higher prices, and when will laboratory services achieve stable profitability?

Order Growth Outpaces Revenue

A more forward-looking indicator than profit growth comes from the order pipeline. In Q1 2026, JOINN reported new contract signings of approximately 910 million yuan, a 111.6% year-on-year increase. The backlog of orders as of the end of March stood at about 3.1 billion yuan, up 40.9% from the previous year.

Concurrently, net cash flow from operating activities increased 95.88% to 128 million yuan, and contract liabilities (advances from customers) rose from 854 million yuan at the end of 2025 to 1.041 billion yuan. These figures suggest synchronized improvement in orders, prepayments, and cash flow, indicating that client R&D budgets are beginning to flow back into the company's financials.

For non-clinical CRO revenue, there is typically a lag of several quarters between contract signing and revenue recognition, due to processes like experiment scheduling, sample analysis, and report delivery. Therefore, a crucial observation period for JOINN lies in the second half of 2026 and into 2027. Key points to monitor will be the conversion rate of the 3.1 billion yuan order backlog into revenue, potential increases in capacity utilization, and whether new contract pricing post-clearance of low-margin projects will support better gross margins.

Shifts in Client Funding Environment

The funding landscape for clients is also evolving. In the first half of 2026, potential deal values disclosed for out-licensing agreements involving Chinese innovative drugs totaled approximately $110 billion across 81 transactions. While this figure includes future milestone payments and does not equate to immediate cash for biotech firms, it signals a marked increase in purchasing interest from multinational pharmaceutical companies for Chinese pipelines.

During the same period, financing for biotech companies also showed recovery. This layered recovery, where funding concentrates on projects with clear clinical data and validated targets, is relatively favorable for the safety evaluation segment. Projects entering the IND preparation phase have typically passed internal screening, making their R&D budgets more certain than those for early-stage concept validation.

JOINN's rapid growth in new orders coincides with the uptick in Chinese biotech licensing deals and improved financing for mature pipelines. If subsequent capital from overseas licensing deals continues to feed into R&D expenditures, pre-clinical CROs like JOINN could experience a demand release earlier than commercial-stage service providers. As a domestic leader in non-clinical safety evaluation, JOINN is highly sensitive to shifts in innovative drug capital expenditure and serves as a relevant industry bellwether.

However, several steps remain between order growth and profit realization. Extended project cycles, client adjustments to R&D timelines, and a high proportion of low-priced contracts can all weaken the translation of orders into revenue and margin improvement. The true test of an industry recovery translating into operational quality will be whether the gap between order growth and revenue growth gradually narrows.

Evolving Competitive Landscape

A longer-term shift facing JOINN stems from advancements in drug evaluation methodologies. Regulatory bodies are increasingly promoting non-animal testing methods. In this context, industry competition is poised for a new hierarchy. While a large inventory of laboratory monkeys can provide a temporary supply advantage, long-term competitive barriers will increasingly derive from experience evaluating complex drugs, cross-regulatory submission expertise, toxicology models, organoid platforms, and data integration capabilities.

JOINN is already engaged in research on models like liver organoids and spinal cord organoids. The company is also gradually bringing a new 20,000-square-meter facility in Suzhou online. These moves provide a foundation for evolving into a comprehensive non-clinical R&D platform, though the commercial success of these R&D investments into billable methodologies remains to be validated by market orders.

This redefines the moat for safety evaluation firms. Simply owning more animals addresses capacity and supply. For complex therapies like ADCs, cell and gene therapies, and oligonucleotides, clients are more concerned with whether evaluation protocols gain regulatory acceptance across different regions and if a single platform can concurrently handle toxicology, bioanalysis, pharmacokinetics, and regulatory support.

Domestic Recovery vs. International Execution

JOINN's international expansion presents another dimension. In 2025, the company recorded an 81.5 million yuan goodwill impairment for its U.S. subsidiary, Biomere, due to a slower-than-expected recovery in the overseas market. This highlights that while the company has a significant international footprint, the recovery of domestic orders and overseas client demand are not synchronized. The international business still needs to address challenges related to capacity utilization, client acquisition, and cost control.

A recovery in domestic pre-clinical demand can improve utilization of existing facilities. However, the ability to generate profitable contributions from international operations will influence JOINN's overall growth ceiling. In the coming years, competition in the non-clinical CRO space will gradually extend from the scale of animal resources to multi-technology platforms, global regulatory expertise, and service capabilities for complex drugs.

Focus for the Coming Quarters

For the next few quarters, the market should closely monitor the gross margin of laboratory services, operating cash flow, contract liabilities, and the conversion rate of the order backlog. Continued increases in monkey prices will provide ongoing earnings flexibility from the balance sheet. However, sustained improvement in the core business gross margin is needed for the industry recovery to progress from the order-taking phase to the operational quality phase.

JOINN has provided evidence that the CXO sector is moving off its bottom, but it has not yet delivered a definitive answer for a full, sustainable upturn. The income statement can thaw rapidly, but rebuilding robust industrial capabilities takes considerably more time.